J.W. Cole Advisors Inc. Purchases 1,569 Shares of Danaher Corporation $DHR

J.W. Cole Advisors Inc. boosted its position in Danaher Corporation (NYSE:DHR) by 54.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,429 shares of the conglomerate’s stock after buying an additional 1,569 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Danaher were worth $875,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. North Star Asset Management Inc. lifted its position in shares of Danaher by 3.7% in the second quarter. North Star Asset Management Inc. now owns 117,564 shares of the conglomerate’s stock worth $23,224,000 after purchasing an additional 4,158 shares in the last quarter. Advisors Asset Management Inc. increased its stake in Danaher by 11.2% in the 2nd quarter. Advisors Asset Management Inc. now owns 7,218 shares of the conglomerate’s stock valued at $1,426,000 after buying an additional 725 shares during the last quarter. Laurel Wealth Advisors LLC lifted its position in Danaher by 19,646.1% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 204,570 shares of the conglomerate’s stock worth $40,411,000 after buying an additional 203,534 shares in the last quarter. South Plains Financial Inc. boosted its stake in shares of Danaher by 30.8% during the 2nd quarter. South Plains Financial Inc. now owns 1,109 shares of the conglomerate’s stock worth $219,000 after buying an additional 261 shares during the last quarter. Finally, CreativeOne Wealth LLC boosted its stake in shares of Danaher by 38.6% during the 2nd quarter. CreativeOne Wealth LLC now owns 2,432 shares of the conglomerate’s stock worth $480,000 after buying an additional 677 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Buying and Selling at Danaher

In other Danaher news, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the sale, the senior vice president owned 14,553 shares of the company’s stock, valued at approximately $3,190,454.19. This represents a 59.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 30,248 shares of company stock valued at $6,609,663 in the last three months. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Down 1.0%

DHR stock opened at $226.24 on Monday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $258.23. The business’s 50 day simple moving average is $212.20 and its 200 day simple moving average is $203.31. The company has a current ratio of 1.52, a quick ratio of 1.10 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $159.81 billion, a PE ratio of 46.65, a PEG ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the business posted $1.71 earnings per share. As a group, research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were paid a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. Danaher’s dividend payout ratio is 26.39%.

Analysts Set New Price Targets

DHR has been the topic of several analyst reports. Wells Fargo & Company reiterated a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Bank of America lowered their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Cowen reissued a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. JPMorgan Chase & Co. raised their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research note on Wednesday, October 22nd. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.